loading
전일 마감가:
$1.55
열려 있는:
$1.58
하루 거래량:
348.21K
Relative Volume:
0.79
시가총액:
$90.55M
수익:
$21.05M
순이익/손실:
$-89.22M
주가수익비율:
-0.8939
EPS:
-1.79
순현금흐름:
$-64.50M
1주 성능:
+0.00%
1개월 성능:
+25.98%
6개월 성능:
-67.68%
1년 성능:
-81.50%
1일 변동 폭
Value
$1.56
$1.6499
1주일 범위
Value
$1.48
$1.65
52주 변동 폭
Value
$1.02
$9.69

Tscan Therapeutics Inc Stock (TCRX) Company Profile

Name
명칭
Tscan Therapeutics Inc
Name
전화
857-399-9500
Name
주소
880 WINTER STREET, WALTHAM
Name
직원
195
Name
트위터
Name
다음 수익 날짜
2025-03-05
Name
최신 SEC 제출 서류
Name
TCRX's Discussions on Twitter

TCRX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
TCRX
Tscan Therapeutics Inc
1.60 90.55M 21.05M -89.22M -64.50M -1.79
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-05-16 개시 BTIG Research Buy
2024-05-13 개시 Needham Buy
2023-06-22 개시 Wedbush Outperform

Tscan Therapeutics Inc 주식(TCRX)의 최신 뉴스

pulisher
Apr 30, 2025

BlackRock, Inc. Reduces Stake in TScan Therapeutics Inc by 43.05% - GuruFocus

Apr 30, 2025
pulisher
Apr 29, 2025

Geode Capital Management LLC Has $2.93 Million Stock Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

TScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual Meeting - Nasdaq

Apr 28, 2025
pulisher
Apr 28, 2025

TScan Therapeutics Announces Upcoming Presentation at the - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

TScan Unveils Groundbreaking CD45-Targeted Cell Therapy Research at Major ASGCT Conference - Stock Titan

Apr 28, 2025
pulisher
Apr 22, 2025

What is the investor’s view on Tscan Therapeutics Inc (TCRX)? - uspostnews.com

Apr 22, 2025
pulisher
Apr 17, 2025

Investing in Tscan Therapeutics Inc (TCRX) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - uspostnews.com

Apr 17, 2025
pulisher
Apr 12, 2025

Prudential Financial Inc. Acquires Shares of 10,415 TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $9.33 Average PT from Brokerages - Defense World

Apr 11, 2025
pulisher
Apr 09, 2025

TScan Therapeutics’ (TCRX) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World

Apr 09, 2025
pulisher
Apr 08, 2025

Tscan Therapeutics Inc (TCRX) deserves deeper analysis - uspostnews.com

Apr 08, 2025
pulisher
Apr 08, 2025

Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts - Benzinga

Apr 08, 2025
pulisher
Apr 01, 2025

Monitoring Gentherm Inc (THRM) after recent insider movements - knoxdaily.com

Apr 01, 2025
pulisher
Apr 01, 2025

TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Mar 31, 2025
pulisher
Mar 28, 2025

Tscan Therapeutics Inc [TCRX] Shares Fall Approximately -81.72% Over the Year - Knox Daily

Mar 28, 2025
pulisher
Mar 27, 2025

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access - Quantisnow

Mar 27, 2025
pulisher
Mar 27, 2025

Cell Therapy Veteran With 16 Successful Launches Joins TScan Leadership - Stock Titan

Mar 27, 2025
pulisher
Mar 17, 2025

TScan Therapeutics’ (TCRX) Overweight Rating Reiterated at Morgan Stanley - The AM Reporter

Mar 17, 2025
pulisher
Mar 17, 2025

Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $9.33 - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

TScan Therapeutics (NASDAQ:TCRX) Earns Overweight Rating from Morgan Stanley - Defense World

Mar 16, 2025
pulisher
Mar 14, 2025

Weekly Investment Analysts’ Ratings Changes for TScan Therapeutics (TCRX) - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

TScan Therapeutics’ SWOT analysis: biotech stock navigates clinical milestones By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 13, 2025

HC Wainwright Expects Weaker Earnings for TScan Therapeutics - MarketBeat

Mar 13, 2025
pulisher
Mar 12, 2025

Positive Buy Rating for TScan Therapeutics Driven by Promising Clinical Data and Strong Financial Position - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

TScan Therapeutics’ SWOT analysis: biotech stock navigates clinical milestones - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Head to Head Analysis: TScan Therapeutics (NASDAQ:TCRX) versus Novavax (NASDAQ:NVAX) - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Analysts Set Expectations for TCRX FY2029 Earnings - MarketBeat

Mar 11, 2025
pulisher
Mar 11, 2025

TScan Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Mar 11, 2025
pulisher
Mar 10, 2025

Q2 EPS Estimate for TScan Therapeutics Lowered by Analyst - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

Wedbush Equities Analysts Cut Earnings Estimates for TCRX - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Research Analysts Set Expectations for TCRX FY2029 Earnings - Defense World

Mar 09, 2025
pulisher
Mar 09, 2025

Barclays Issues Pessimistic Forecast for TScan Therapeutics (NASDAQ:TCRX) Stock Price - Defense World

Mar 09, 2025
pulisher
Mar 09, 2025

TScan Therapeutics’ (TCRX) Buy Rating Reiterated at HC Wainwright - Defense World

Mar 09, 2025
pulisher
Mar 07, 2025

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025 (NASDAQ:TCRX) - Seeking Alpha

Mar 07, 2025
pulisher
Mar 07, 2025

HC Wainwright Reiterates "Buy" Rating for TScan Therapeutics (NASDAQ:TCRX) - MarketBeat

Mar 07, 2025
pulisher
Mar 07, 2025

TScan Therapeutics price target lowered to $3 from $14 at Barclays - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Needham & Company LLC Issues Pessimistic Forecast for TScan Therapeutics (NASDAQ:TCRX) Stock Price - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

TScan Therapeutics (NASDAQ:TCRX) Earns Outperform Rating from Wedbush - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

H.C. Wainwright maintains $15 target on Tscan shares By Investing.com - Investing.com Canada

Mar 07, 2025
pulisher
Mar 06, 2025

TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight - GlobeNewswire Inc.

Mar 06, 2025
pulisher
Mar 06, 2025

H.C. Wainwright maintains $15 target on Tscan shares - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

Breaking Down TScan Therapeutics: 4 Analysts Share Their Views - Benzinga

Mar 06, 2025
pulisher
Mar 06, 2025

TCR Therapy Clinical Trial Pipeline Accelerates as 80+ - GlobeNewswire

Mar 06, 2025
pulisher
Mar 05, 2025

TScan Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million -March 05, 2025 at 04:54 pm EST - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Tscan Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com UK

Mar 05, 2025
pulisher
Mar 05, 2025

TScan Therapeutics reports Q4 EPS (30c), consensus (28c) - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 05, 2025
pulisher
Mar 05, 2025

TScan Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 05, 2025

Tscan Therapeutics Inc (TCRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
자본화:     |  볼륨(24시간):